Clinical trial
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy…
NCT00192049 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00192049 |
|---|---|
| Title | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer |
| Official title | A Randomized Phase II Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Superficial Bladder Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, mitomycin C |
| Enrollment | 90 |
| Start date | Dec 1, 2003 |
| Completion | Apr 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | May 17, 2007 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: